William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...
Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...
French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...
Investor's Business Daily on MSN
This biotech name outperforms 93% of stocks, and it's in a buy zone
Mirum's recent jump lifted it past a 74.96 entry of a pattern resembling a double-bottom base. It also broke out of a ...
Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...
Geron Corporation, a Bay Area biotech company that’s ramping up sales of its first commercial drug, announced on Thursday ...
TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...
The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...
One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...
Ironwood Pharmaceuticals Inc. has figured out a deal to settle a lawsuit filed against VectivBio, a biotech it bought in 2023 ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback